Exploring the Contribution of the Transporter AGT1/rBAT in Cystinuria Progression: Insights from Mouse Models and a Retrospective Cohort Study

dc.contributor.authorGràcia-Garcia, Silvia
dc.contributor.authorMayayo Vallverdú, Clara
dc.contributor.authorPrat, Esther
dc.contributor.authorVecino-Pérez, Marta
dc.contributor.authorGonzález, Laura
dc.contributor.authorSan Miguel, Luz
dc.contributor.authorLopera, Noelia
dc.contributor.authorArias, Ángela
dc.contributor.authorArtuch, Rafael
dc.contributor.authorLópez de Heredia, Miguel
dc.contributor.authorTorrecilla, Carlos
dc.contributor.authorRousaud-Barón, Ferran
dc.contributor.authorAngerri, Oriol
dc.contributor.authorErrasti-Murugarren, Ekaitz
dc.contributor.authorNunes Martínez, Virginia
dc.date.accessioned2024-03-08T18:24:14Z
dc.date.available2024-03-08T18:24:14Z
dc.date.issued2023-12-05
dc.date.updated2024-03-08T18:24:14Z
dc.description.abstractMore than 20 years have passed since the identification of SLC3A1 and SLC7A9 as causative genes for cystinuria. However, cystinuria patients exhibit significant variability in the age of lithiasis onset, recurrence, and response to treatment, suggesting the presence of modulatory factors influencing cystinuria severity. In 2016, a second renal cystine transporter, AGT1, encoded by the SLC7A13 gene, was discovered. Although it was discarded as a causative gene for cystinuria, its possible effect as a modulatory gene remains unexplored. Thus, we analyzed its function in mouse models of cystinuria, screened the SLC7A13 gene in 34 patients with different lithiasic phenotypes, and functionally characterized the identified variants. Mice results showed that AGT1/rBAT may have a protective role against cystine lithiasis. In addition, among the four missense variants detected in patients, two exhibited a 25% impairment in AGT1/rBAT transport. However, no correlation between SLC7A13 genotypes and lithiasis phenotypes was observed in patients, probably because these variants were found in heterozygous states. In conclusion, our results, consistent with a previous study, suggest that AGT1/rBAT does not have a relevant effect on cystinuria patients, although an impact in patients carrying homozygous pathogenic variants cannot be discarded.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec743629
dc.identifier.issn1661-6596
dc.identifier.pmid38138969
dc.identifier.urihttps://hdl.handle.net/2445/208552
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms242417140
dc.relation.ispartofInternational Journal of Molecular Sciences, 2023, vol. 24, num.24
dc.relation.urihttps://doi.org/10.3390/ijms242417140
dc.rightscc-by (c) Mayayo-Vallverdú, C. et al., 2023
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)
dc.subject.classificationCistinúria
dc.subject.classificationRonyó
dc.subject.classificationCàlculs renals
dc.subject.otherCystinuria
dc.subject.otherKidney
dc.subject.otherKidney calculi
dc.titleExploring the Contribution of the Transporter AGT1/rBAT in Cystinuria Progression: Insights from Mouse Models and a Retrospective Cohort Study
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
845268.pdf
Mida:
2.02 MB
Format:
Adobe Portable Document Format